Effects of testosterone replacement in middle-aged men with dysthymia: a randomized, placebo-controlled clinical trial
Mid-life onset male dysthymic disorder (DD) seems to be a distinct clinical condition with limited therapeutic options. Testosterone replacement is mood-enhancing and has been proposed as an antidepressant therapy, though this strategy has received limited systematic study. We therefore conducted a...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical psychopharmacology 2009-06, Vol.29 (3), p.216-221 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 221 |
|---|---|
| container_issue | 3 |
| container_start_page | 216 |
| container_title | Journal of clinical psychopharmacology |
| container_volume | 29 |
| creator | Seidman, Stuart N Orr, Guy Raviv, Gil Levi, Rachel Roose, Steven P Kravitz, Efrat Amiaz, Revital Weiser, Mark |
| description | Mid-life onset male dysthymic disorder (DD) seems to be a distinct clinical condition with limited therapeutic options. Testosterone replacement is mood-enhancing and has been proposed as an antidepressant therapy, though this strategy has received limited systematic study. We therefore conducted a six-week double-blind placebo-controlled clinical trial in 23 men with DD and with low or low-normal testosterone (T) level (i.e, screening total serum testosterone |
| doi_str_mv | 10.1097/JCP.0b013e3181a39137 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_745974829</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>745974829</sourcerecordid><originalsourceid>FETCH-LOGICAL-c337t-ab2acced136c41439f2e57333f82b081573a74c5a79b0c4a2464cfbd521224b63</originalsourceid><addsrcrecordid>eNp9kU1rGzEQhkVpiJ2Pf1CKTu0l60ga7crbWzDOF4b0kEBvi1aarVW0K1eSG9xfn21sKOSQ0wzD874wPIR84mzGWa0u7xffZ6xlHBD4nGuoOagPZMpLgEJx8eMjmTKheMGUrCfkJKVfjHGpRHlMJryWkjEFU_Jn2XVocqKhoxlTDiljDAPSiBuvDfY4ZOoG2jtrPRb6J1o63uizy2tqdymvd73T36imUQ829O4v2gv6Gm1DYcKQY_B-DBnvBme0pzk67c_IUad9wvPDPCVP18vHxW2xeri5W1ytCgOgcqFboY1By6EykkuoO4GlAoBuLlo25-OulTSlVnXLjNRCVtJ0rS0FF0K2FZySr_veTQy_t-N_Te-SQe_1gGGbGiXLWsm5qEfyy7tkpQRUslIjKPegiSGliF2zia7Xcddw1vwz04xmmrdmxtjnQ_-27dH-Dx1UwAvunovO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67236467</pqid></control><display><type>article</type><title>Effects of testosterone replacement in middle-aged men with dysthymia: a randomized, placebo-controlled clinical trial</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Seidman, Stuart N ; Orr, Guy ; Raviv, Gil ; Levi, Rachel ; Roose, Steven P ; Kravitz, Efrat ; Amiaz, Revital ; Weiser, Mark</creator><creatorcontrib>Seidman, Stuart N ; Orr, Guy ; Raviv, Gil ; Levi, Rachel ; Roose, Steven P ; Kravitz, Efrat ; Amiaz, Revital ; Weiser, Mark</creatorcontrib><description>Mid-life onset male dysthymic disorder (DD) seems to be a distinct clinical condition with limited therapeutic options. Testosterone replacement is mood-enhancing and has been proposed as an antidepressant therapy, though this strategy has received limited systematic study. We therefore conducted a six-week double-blind placebo-controlled clinical trial in 23 men with DD and with low or low-normal testosterone (T) level (i.e, screening total serum testosterone <350 ng/dL). Enrolled men were randomized to receive intramuscular injections of 200 mg of testosterone cypionate or placebo every 10 days. The primary outcome measures were the Clinical Global Impression (CGI) improvement score and the 21-item Hamilton Depression Rating Scale (HDRS) score.Twenty-three patients were randomized. The mean (SD) age of the enrolled patients was 50.6 (7.0) years and that of total testosterone level was 339 (93) ng/dL. The median duration of the current dysthymic episode was 3.6 (2.3) years, and the mean (SD) HDRS was 14.0 (2.9). After the intervention, the mean HDRS score decreased significantly more in the testosterone group (7.46 [4.56]) than in the placebo group (1.8 [4.13], t21 = -3.07, P = 0.006). Remission, defined as a CGI improvement score of 1 or 2 and a final HDRS score lower than 8, was achieved by 7 (53.8%) of 13 in the testosterone group and 1 (10%) of 10 in the placebo group (P = 0.03). Testosterone replacement may be an effective antidepressant strategy for late-onset male dysthymia.</description><identifier>ISSN: 0271-0749</identifier><identifier>EISSN: 1533-712X</identifier><identifier>DOI: 10.1097/JCP.0b013e3181a39137</identifier><identifier>PMID: 19440073</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Aged ; Androgens - therapeutic use ; Double-Blind Method ; Dysthymic Disorder - drug therapy ; Humans ; Injections, Intramuscular ; Male ; Middle Aged ; Psychiatric Status Rating Scales ; Psychometrics ; Remission Induction - methods ; Severity of Illness Index ; Testosterone - analogs & derivatives ; Testosterone - blood ; Testosterone - therapeutic use ; Treatment Outcome</subject><ispartof>Journal of clinical psychopharmacology, 2009-06, Vol.29 (3), p.216-221</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c337t-ab2acced136c41439f2e57333f82b081573a74c5a79b0c4a2464cfbd521224b63</citedby><cites>FETCH-LOGICAL-c337t-ab2acced136c41439f2e57333f82b081573a74c5a79b0c4a2464cfbd521224b63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19440073$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Seidman, Stuart N</creatorcontrib><creatorcontrib>Orr, Guy</creatorcontrib><creatorcontrib>Raviv, Gil</creatorcontrib><creatorcontrib>Levi, Rachel</creatorcontrib><creatorcontrib>Roose, Steven P</creatorcontrib><creatorcontrib>Kravitz, Efrat</creatorcontrib><creatorcontrib>Amiaz, Revital</creatorcontrib><creatorcontrib>Weiser, Mark</creatorcontrib><title>Effects of testosterone replacement in middle-aged men with dysthymia: a randomized, placebo-controlled clinical trial</title><title>Journal of clinical psychopharmacology</title><addtitle>J Clin Psychopharmacol</addtitle><description>Mid-life onset male dysthymic disorder (DD) seems to be a distinct clinical condition with limited therapeutic options. Testosterone replacement is mood-enhancing and has been proposed as an antidepressant therapy, though this strategy has received limited systematic study. We therefore conducted a six-week double-blind placebo-controlled clinical trial in 23 men with DD and with low or low-normal testosterone (T) level (i.e, screening total serum testosterone <350 ng/dL). Enrolled men were randomized to receive intramuscular injections of 200 mg of testosterone cypionate or placebo every 10 days. The primary outcome measures were the Clinical Global Impression (CGI) improvement score and the 21-item Hamilton Depression Rating Scale (HDRS) score.Twenty-three patients were randomized. The mean (SD) age of the enrolled patients was 50.6 (7.0) years and that of total testosterone level was 339 (93) ng/dL. The median duration of the current dysthymic episode was 3.6 (2.3) years, and the mean (SD) HDRS was 14.0 (2.9). After the intervention, the mean HDRS score decreased significantly more in the testosterone group (7.46 [4.56]) than in the placebo group (1.8 [4.13], t21 = -3.07, P = 0.006). Remission, defined as a CGI improvement score of 1 or 2 and a final HDRS score lower than 8, was achieved by 7 (53.8%) of 13 in the testosterone group and 1 (10%) of 10 in the placebo group (P = 0.03). Testosterone replacement may be an effective antidepressant strategy for late-onset male dysthymia.</description><subject>Adult</subject><subject>Aged</subject><subject>Androgens - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Dysthymic Disorder - drug therapy</subject><subject>Humans</subject><subject>Injections, Intramuscular</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychometrics</subject><subject>Remission Induction - methods</subject><subject>Severity of Illness Index</subject><subject>Testosterone - analogs & derivatives</subject><subject>Testosterone - blood</subject><subject>Testosterone - therapeutic use</subject><subject>Treatment Outcome</subject><issn>0271-0749</issn><issn>1533-712X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1rGzEQhkVpiJ2Pf1CKTu0l60ga7crbWzDOF4b0kEBvi1aarVW0K1eSG9xfn21sKOSQ0wzD874wPIR84mzGWa0u7xffZ6xlHBD4nGuoOagPZMpLgEJx8eMjmTKheMGUrCfkJKVfjHGpRHlMJryWkjEFU_Jn2XVocqKhoxlTDiljDAPSiBuvDfY4ZOoG2jtrPRb6J1o63uizy2tqdymvd73T36imUQ829O4v2gv6Gm1DYcKQY_B-DBnvBme0pzk67c_IUad9wvPDPCVP18vHxW2xeri5W1ytCgOgcqFboY1By6EykkuoO4GlAoBuLlo25-OulTSlVnXLjNRCVtJ0rS0FF0K2FZySr_veTQy_t-N_Te-SQe_1gGGbGiXLWsm5qEfyy7tkpQRUslIjKPegiSGliF2zia7Xcddw1vwz04xmmrdmxtjnQ_-27dH-Dx1UwAvunovO</recordid><startdate>200906</startdate><enddate>200906</enddate><creator>Seidman, Stuart N</creator><creator>Orr, Guy</creator><creator>Raviv, Gil</creator><creator>Levi, Rachel</creator><creator>Roose, Steven P</creator><creator>Kravitz, Efrat</creator><creator>Amiaz, Revital</creator><creator>Weiser, Mark</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope></search><sort><creationdate>200906</creationdate><title>Effects of testosterone replacement in middle-aged men with dysthymia: a randomized, placebo-controlled clinical trial</title><author>Seidman, Stuart N ; Orr, Guy ; Raviv, Gil ; Levi, Rachel ; Roose, Steven P ; Kravitz, Efrat ; Amiaz, Revital ; Weiser, Mark</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c337t-ab2acced136c41439f2e57333f82b081573a74c5a79b0c4a2464cfbd521224b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Androgens - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Dysthymic Disorder - drug therapy</topic><topic>Humans</topic><topic>Injections, Intramuscular</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychometrics</topic><topic>Remission Induction - methods</topic><topic>Severity of Illness Index</topic><topic>Testosterone - analogs & derivatives</topic><topic>Testosterone - blood</topic><topic>Testosterone - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Seidman, Stuart N</creatorcontrib><creatorcontrib>Orr, Guy</creatorcontrib><creatorcontrib>Raviv, Gil</creatorcontrib><creatorcontrib>Levi, Rachel</creatorcontrib><creatorcontrib>Roose, Steven P</creatorcontrib><creatorcontrib>Kravitz, Efrat</creatorcontrib><creatorcontrib>Amiaz, Revital</creatorcontrib><creatorcontrib>Weiser, Mark</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><jtitle>Journal of clinical psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Seidman, Stuart N</au><au>Orr, Guy</au><au>Raviv, Gil</au><au>Levi, Rachel</au><au>Roose, Steven P</au><au>Kravitz, Efrat</au><au>Amiaz, Revital</au><au>Weiser, Mark</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of testosterone replacement in middle-aged men with dysthymia: a randomized, placebo-controlled clinical trial</atitle><jtitle>Journal of clinical psychopharmacology</jtitle><addtitle>J Clin Psychopharmacol</addtitle><date>2009-06</date><risdate>2009</risdate><volume>29</volume><issue>3</issue><spage>216</spage><epage>221</epage><pages>216-221</pages><issn>0271-0749</issn><eissn>1533-712X</eissn><abstract>Mid-life onset male dysthymic disorder (DD) seems to be a distinct clinical condition with limited therapeutic options. Testosterone replacement is mood-enhancing and has been proposed as an antidepressant therapy, though this strategy has received limited systematic study. We therefore conducted a six-week double-blind placebo-controlled clinical trial in 23 men with DD and with low or low-normal testosterone (T) level (i.e, screening total serum testosterone <350 ng/dL). Enrolled men were randomized to receive intramuscular injections of 200 mg of testosterone cypionate or placebo every 10 days. The primary outcome measures were the Clinical Global Impression (CGI) improvement score and the 21-item Hamilton Depression Rating Scale (HDRS) score.Twenty-three patients were randomized. The mean (SD) age of the enrolled patients was 50.6 (7.0) years and that of total testosterone level was 339 (93) ng/dL. The median duration of the current dysthymic episode was 3.6 (2.3) years, and the mean (SD) HDRS was 14.0 (2.9). After the intervention, the mean HDRS score decreased significantly more in the testosterone group (7.46 [4.56]) than in the placebo group (1.8 [4.13], t21 = -3.07, P = 0.006). Remission, defined as a CGI improvement score of 1 or 2 and a final HDRS score lower than 8, was achieved by 7 (53.8%) of 13 in the testosterone group and 1 (10%) of 10 in the placebo group (P = 0.03). Testosterone replacement may be an effective antidepressant strategy for late-onset male dysthymia.</abstract><cop>United States</cop><pmid>19440073</pmid><doi>10.1097/JCP.0b013e3181a39137</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0271-0749 |
| ispartof | Journal of clinical psychopharmacology, 2009-06, Vol.29 (3), p.216-221 |
| issn | 0271-0749 1533-712X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_745974829 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Aged Androgens - therapeutic use Double-Blind Method Dysthymic Disorder - drug therapy Humans Injections, Intramuscular Male Middle Aged Psychiatric Status Rating Scales Psychometrics Remission Induction - methods Severity of Illness Index Testosterone - analogs & derivatives Testosterone - blood Testosterone - therapeutic use Treatment Outcome |
| title | Effects of testosterone replacement in middle-aged men with dysthymia: a randomized, placebo-controlled clinical trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T18%3A38%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20testosterone%20replacement%20in%20middle-aged%20men%20with%20dysthymia:%20a%20randomized,%20placebo-controlled%20clinical%20trial&rft.jtitle=Journal%20of%20clinical%20psychopharmacology&rft.au=Seidman,%20Stuart%20N&rft.date=2009-06&rft.volume=29&rft.issue=3&rft.spage=216&rft.epage=221&rft.pages=216-221&rft.issn=0271-0749&rft.eissn=1533-712X&rft_id=info:doi/10.1097/JCP.0b013e3181a39137&rft_dat=%3Cproquest_cross%3E745974829%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67236467&rft_id=info:pmid/19440073&rfr_iscdi=true |